Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | JAG2 |
| Gene Name: | JAG2 |
| Mass (Da): | 133367 |
| Number AA: | 1238 |
| UniProt ID: | Q9Y219 |
| Locus ID: | 3714 |
| COSMIC ID: | JAG2 |
| Gene location on chromosome: | 14q32 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20420 |
| Percent of cancer specimens with mutations: | 0.78 |
| Normal role description: | JAG2 is a ligand for the NOTCH receptor important in embryonic development and terminal cellular differentiation. The JAG2 ligand is synthesized as a transmembrane protein and will bind NOTCH receptors in a cell-cell contact manner. JAG2 overexpression has been implicated in malignant multiple myeloma. Multiple myeloma malignancies result in increased IL6 production, a required cytokine to enhance myeloma cell proliferation. IL6 production is dependent on JAG2 mediated cell-cell contact. Thus JAG2 propagates cellular proliferation through increased induction of IL6. |